Fulcrum Therapeutics, Inc.
NASDAQ:FULC
4.55 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Fulcrum Therapeutics, Inc. |
Symbool | FULC |
Munteenheid | USD |
Prijs | 4.55 |
Beurswaarde | 245,421,085 |
Dividendpercentage | 0% |
52-weken bereik | 2.86 - 13.7 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Alexander C. Sapir |
Website | https://www.fulcrumtx.com |
An error occurred while fetching data.
Over Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)